ReviewPhytotherapy research : PTR2026
Multitarget Regulatory Mechanisms and Research Advances of Plant-Derived Bioactive Ingredients in Hypertension Prevention and Management.
Review in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Network pharmacology-based investigation on the mechanism of aloin in ameliorating atherosclerosis by regulating macrophage polarization.Journal of molecular histology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hypertension remains a major global risk factor for cardiovascular diseases, yet current treatments face challenges such as suboptimal blood pressure control and inadequate organ protection. Plant-derived bioactive ingredients (PDBIs), with their multi-target and multi-pathway properties, offer novel strategies for hypertension management. This review systematically examines the mechanisms of major PDBIs (flavonoids, terpenoids, alkaloids) in hypertension, focusing on their regulation of vascular function, renin-angiotensin-aldosterone system and sympathetic nervous system, water-salt homeostasis, and target organ protection. Key signaling pathways involved (NF-κB, TGF-β, MAPK, PI3K/Akt) are analyzed. Clinical translation challenges, including low bioavailability and response heterogeneity, are discussed. Future research should integrate systems pharmacology, smart delivery systems, and precision medicine to advance PDBIs from traditional use to evidence-based therapy, providing a theoretical basis for developing novel antihypertensive and organ-protective strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.